Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Ann Rheum Dis ; 70(6): 1138-43, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21389044

RESUMO

OBJECTIVES: Interferon α (IFNα) plays a central role in the pathogenesis of systemic lupus erythematosus (SLE) and is considered a target for its treatment. In the current study, the ability of active immunisation with a human (hu) IFNα2b Kinoid (IFN-K) to break B cell tolerance to IFNα and to induce huIFNα-neutralising antibodies in mice immunotolerant to huIFNα2b was assessed. METHODS: IFN-K was manufactured by crosslinking huIFNα2b to keyhole limpet haemocyanin (KLH). Transgenic mice expressing huIFNα2b received by intramuscular injection either saline or polymerised huIFNα2b as controls, or IFN-K, emulsified in ISA51vg adjuvant. RESULTS: All of the huIFNα2b-expressing mice immunised with IFN-K generated neutralising antibodies against huIFNα2b. In addition, these antibodies neutralised all 13 subtypes of huIFNα. They also neutralised IFNα activity in sera collected from 10 different patients with active SLE. However, the antibodies did not bind to huIFNγ or huIFNß. Finally, cellular activation assays showed that immunisation with IFN-K did not induce memory T cells reactive to native huIFNα2b, whereas it did induce memory cells reactive to KLH. CONCLUSION: These results show that active immunisation with IFN-K induces polyclonal antibodies that neutralise all subtypes of huIFNα as well as IFNα in sera from patients with SLE by breaking humoral but not cellular tolerance to IFNα. This suggests that immunisation with IFN-K is a promising new therapeutic strategy for the treatment of SLE.


Assuntos
Interferon-alfa/imunologia , Lúpus Eritematoso Sistêmico/imunologia , Animais , Relação Dose-Resposta Imunológica , Feminino , Hemocianinas/imunologia , Humanos , Tolerância Imunológica/imunologia , Imunoglobulina G/biossíntese , Memória Imunológica/imunologia , Imunoterapia Ativa/métodos , Interferon alfa-2 , Camundongos , Camundongos Transgênicos , Proteínas Recombinantes , Baço/imunologia , Linfócitos T/imunologia
2.
Blood ; 113(14): 3235-44, 2009 Apr 02.
Artigo em Inglês | MEDLINE | ID: mdl-18978205

RESUMO

Peripheral blood and tissue eosinophilia are a prominent feature in allergic diseases and during helminth infections. Eosinophil recruitment also frequently occurs upon mycobacterial infections, particularly in lung granuloma. However, the mechanism by which eosinophils interact with mycobacteria remains largely unknown. Because eosinophils recently have been shown to be involved in innate immune responses, we investigated the direct interactions of eosinophils with Mycobacterium bovis BCG as a study model. We show that live BCG attracts human eosinophils and induces reactive oxygen species (ROS) synthesis, granule protein release, and tumor necrosis factor (TNF)-alpha secretion. Using anti-TLR2 neutralizing antibodies before exposure of eosinophils to BCG, we showed a critical role of TLR2 signaling in ROS and eosinophil peroxidase release. BCG-induced eosinophil activation is mediated through the p38 mitogen-activated protein (MAP) kinase and nuclear factor (NF)-kappaB pathways. In addition, a mycobacterial wall component, lipomannan, induced a TLR2-dependent eosinophil activation. In addition, we showed that eosinophils express and produce alpha-defensins upon stimulation with BCG and lipomannan and that alpha-defensins could inhibit mycobacterial growth in synergy with eosinophil cationic protein. These results suggest a role for human eosinophils as direct effectors in TLR2-mediated innate immunity against mycobacteria and confer to these cells potent cytotoxic functions through defensin and eosinophil cationic protein production.


Assuntos
Eosinófilos/fisiologia , Mycobacterium bovis/imunologia , Receptor 2 Toll-Like/fisiologia , alfa-Defensinas/fisiologia , Células Cultivadas , Citotoxicidade Imunológica/fisiologia , Eosinófilos/imunologia , Eosinófilos/metabolismo , Humanos , Imunidade Inata/imunologia , Imunidade Inata/fisiologia , Mycobacterium bovis/crescimento & desenvolvimento , Mycobacterium bovis/metabolismo , Fator 88 de Diferenciação Mieloide/fisiologia , NF-kappa B/metabolismo , NF-kappa B/fisiologia , Receptor 2 Toll-Like/metabolismo , Receptor 4 Toll-Like/metabolismo , alfa-Defensinas/metabolismo , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo , Proteínas Quinases p38 Ativadas por Mitógeno/fisiologia
3.
J Neuropathol Exp Neurol ; 68(6): 633-41, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19458546

RESUMO

Glioblastomas (GBMs) are highly malignant tumors characterized by microvascular proliferation and the pseudopalisading pattern of necrosis. Investigations have, therefore, focused on vascular and endothelial cell biology in GBM. Endocan, also called endothelial cell-specific molecule-1, is a proteoglycan that is secreted by endothelial cells and upregulated by proangiogenic factors. We found that endocan is not only expressed in vitro by endothelial cells but also in the T98G and U118MG human GBM cell lines. In U118MG cells, tumor necrosis factor and fibroblast growth factor 2 upregulated endocan production, whereas exposure to hypoxia or cobalt chloride, an inducer of hypoxia inducible factor 1, increased endocan release without affecting cell viability. Endocan expression in 82 brain tumors was studied by immunohistochemistry. Endocan immunoreactivity was detected in hyperplastic endothelial cells in high-grade gliomas, mostly at the tumor margins; endothelial cells were mostly endocan negative in low-grade gliomas, and it was never detected in the cerebral cortex distant from the tumors. Tumor cells in high-grade but not low-grade gliomas also expressed endocan, and it was detected in palisading cells surrounding areas of necrosis in GBM. Endothelial cell endocan immunoreactivity also correlated with shorter survival in glioma patients. Taken together, these results suggest that endocan is associated with abnormal vasculature in high-grade gliomas.


Assuntos
Neoplasias Encefálicas/metabolismo , Regulação Neoplásica da Expressão Gênica/fisiologia , Glioblastoma/metabolismo , Proteínas de Neoplasias/metabolismo , Proteoglicanas/metabolismo , Adulto , Idoso , Neoplasias Encefálicas/classificação , Neoplasias Encefálicas/mortalidade , Linhagem Celular Tumoral , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Seguimentos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Glioblastoma/classificação , Glioblastoma/mortalidade , Humanos , Hipóxia/metabolismo , Hipóxia/fisiopatologia , Masculino , Pessoa de Meia-Idade , Análise de Sobrevida , Fatores de Tempo , Fator de Necrose Tumoral alfa/farmacologia
4.
Biochem Biophys Res Commun ; 369(2): 297-302, 2008 May 02.
Artigo em Inglês | MEDLINE | ID: mdl-18261977

RESUMO

Standard culture systems of eukaryotic cells generally failed to deliver sufficient amounts of recombinant proteins without increasing the costs of production. We here showed that membrane-based bioreactors, initially developed for the production of monoclonal antibodies, can be very useful for the production using engineered HEK293 cells, of a recombinant proteoglycan called endocan, with achievement of high level expression and efficient long-term production. When compared to standard procedures, the growth in suspension and at high density of these cells in one bioreactor promoted a 60-fold increase of the concentration of the soluble recombinant endocan. These culture conditions did not affect cell viability, stable expression, recognition by specific monoclonal antibodies or electrophoretic profile of the recombinant endocan. Such an easy to scale up system to produce recombinant protein should open soon new opportunities to study structure and functions of endocan or any other glycosylated cell products newly investigated.


Assuntos
Reatores Biológicos , Técnicas de Cultura de Células/métodos , Rim/fisiologia , Membranas Artificiais , Proteínas de Neoplasias/biossíntese , Engenharia de Proteínas/métodos , Proteoglicanas/biossíntese , Proteínas Recombinantes/biossíntese , Linhagem Celular , Humanos , Proteínas de Neoplasias/genética , Proteoglicanas/genética
5.
BMC Cancer ; 8: 14, 2008 Jan 18.
Artigo em Inglês | MEDLINE | ID: mdl-18205914

RESUMO

BACKGROUND: Endocan was originally described as a dermatan sulfate proteoglycan found freely circulating in the blood. Endocan expression confers tumorigenic properties to epithelial cell lines or accelerate the growth of already tumorigenic cells. This molecule is the product of a single gene composed of 3 exons. Previous data showed that endocan mRNA is subject to alternative splicing with possible generation of two protein products. In the present study we identified, and functionally characterized, the alternative spliced product of the endocan gene: the exon 2-deleted endocan, called endocanDelta2. METHODS: Stable, endocanDelta2-overexpressing cell lines were generated to investigate the biological activities of this new alternatively spliced product of endocan gene. Tumorigenesis was studied by inoculating endocan and endocanDelta2 expressing cell lines subcutaneously in SCID mice. Biochemical properties of endocan and endocanDelta2 were studied after production of recombinant proteins in various cell lines of human and murine origin. RESULTS: Our results showed that the exon 2 deletion impairs synthesis of the glycan chain, known to be involved in the pro-tumoral effect of endocan. EndocanDelta2 did not promote tumor formation by 293 cells implanted in the skin of severe combined immunodeficient (SCID) mice. CONCLUSION: Our results emphasize the key role of the polypeptide sequence encoded by the exon 2 of endocan gene in tumorigenesis, and suggest that this sequence could be a target for future therapies against cancer.


Assuntos
Transformação Celular Neoplásica/genética , Proteínas de Neoplasias/genética , Proteoglicanas/genética , Processamento Alternativo , Animais , Células CHO , Transformação Celular Neoplásica/metabolismo , Cricetinae , Cricetulus , DNA Complementar/genética , Células Endoteliais/metabolismo , Células Endoteliais/fisiologia , Éxons , Deleção de Genes , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Camundongos , Camundongos SCID , Proteínas de Neoplasias/metabolismo , Polissacarídeos/biossíntese , Isoformas de Proteínas , Proteoglicanas/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Ratos , Reação em Cadeia da Polimerase Via Transcriptase Reversa
6.
Int J Parasitol ; 33(10): 1067-78, 2003 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-13129529

RESUMO

In this study, we investigated how the age of rats would affect the course of infection of and the immune response to Plasmodium berghei. Both young (4-week-old) and adult rats (8-week-old) can be infected with P. berghei ANKA strain, with significantly higher levels of infected red blood cells in young rats. While 100% of young rats succumbed to infection, adult rats were able to clear blood parasites and no mortality was observed. Analysis of cellular distribution and circulating cytokines demonstrated the persistence of CD4+/CD25+ T cells and high expression of circulating interleukin-10 (IL-10) during the progression of infection in young-susceptible rats, whereas high levels of CD8+ T cells and natural killer T cells are detected in adult-resistant rats. Analysis of antibody isotypes showed that adult rats produced significantly higher levels of interferon-gamma (IFN-gamma)-dependent IgG2c antibodies than young rats during infection. Further evaluation of the role of IL-10, IFN-gamma and of immune cells showed that only the adoptive transfer of spleen cells from adult-resistant rats was able to convert susceptibility of young-susceptible rats to a resistant phenotype. These observations suggest that cell-mediated mechanisms are crucial for the control of a primary infection with P. berghei in young rats.


Assuntos
Envelhecimento/imunologia , Malária/imunologia , Plasmodium berghei/imunologia , Transferência Adotiva , Animais , Anticorpos Antiprotozoários/biossíntese , Linfócitos B/imunologia , Citocinas/sangue , Suscetibilidade a Doenças , Interferon gama/imunologia , Interleucina-10/imunologia , Células Matadoras Naturais/imunologia , Macrófagos/imunologia , Malária/prevenção & controle , Masculino , Parasitemia/imunologia , Ratos , Ratos Endogâmicos F344 , Baço/imunologia , Subpopulações de Linfócitos T/imunologia
7.
J Immunol ; 178(3): 1713-22, 2007 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-17237421

RESUMO

In human malaria, children suffer very high rates of morbidity and mortality. To analyze the mechanisms involved in age-dependent protection against malaria, we developed an experimental model of infection in rats, where young rats are susceptible to Plasmodium berghei and adult rats control blood parasites and survive thereafter. In this study, we showed that protection of young rats could be achievable by adoptive transfer of spleen cells from adult protected rats, among which T cells could transfer partial protection. Transcriptome analysis of spleen cells transferring immunity revealed the overexpression of genes mainly expressed by eosinophils and neutrophils. Evaluation of the role of neutrophils showed that these cells were able to transfer partial protection to young rats. This antiparasitic effect was shown to be mediated, at least in part, through the neutrophil protein-1 defensin. Further adoptive transfer experiments indicated an efficient cooperation between neutrophils and T cells in protecting all young recipients. These observations, together with those from in vitro studies in human malaria, suggest that the failure of children to control infection could be related not only to an immaturity of their adaptive immunity but also to a lack in an adequate innate immune response.


Assuntos
Malária/imunologia , Neutrófilos/imunologia , Linfócitos T/imunologia , alfa-Defensinas/imunologia , Transferência Adotiva , Fatores Etários , Animais , Modelos Animais de Doenças , Malária/terapia , Neutrófilos/parasitologia , Plasmodium berghei , Ratos , Baço/citologia , Taxa de Sobrevida , Linfócitos T/parasitologia , Linfócitos T/transplante
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA